<DOC>
	<DOCNO>NCT01043627</DOCNO>
	<brief_summary>Assess tolerability , transition method clinical effect transition sildenafil ( Revatio ) tadalafil ( Adcirca ) treatment pulmonary arterial hypertension .</brief_summary>
	<brief_title>Sildenafil Tadalafil Pulmonary Arterial Hypertension ( SITAR )</brief_title>
	<detailed_description>Sildenafil ( Revatio ) receive approval treatment pulmonary arterial hypertension base upon result SUPER1 study randomize patient sildenafil 20 , 40 80 mg tid match placebo . 1 For open label extension study , patient receive 80 mg tid . Following analysis data , FDA approve 20 mg tid , indicate `` high dos recommend '' ( Revatio PDR package insert ) . Although significant difference dose group overall cohort regard 6 minute walk , patient idiopathic PAH great hemodynamic effect 80 mg tid dose , raise possibility maximum approve dose maximally hemodynamically effective dose least patient subset . This result confusing situation clinician treat patient sildenafil dos substantially FDA recommend dose , create issue cost insurance coverage . Some patient receive five 20 mg Revatio ( sildenafil PH ) tablets tid , increase cost fivefold ( RPFrantz , unpublished data ) . Tadalafil ( Adcirca ) receive FDA approval treatment PAH May 2009 , available indication August 2009 . The pivotal Pulmonary Arterial Hypertension Response Tadalafil ( PHIRST ) study randomize 405 patient WHO group I PAH either treatment na√Øve background therapy bosentan , receive placebo , 2.5 , 10 , 20 40 mg daily.2 A dose response observe , 40 mg daily meeting primary endpoint improvement 6 minute walk 16 week ( placebo-corrected treatment effect 33 , p &lt; 0.01 ) , composite time clinical worsening endpoint also meet . The FDA approve dose tadalafil PAH 40 mg ( two 20 mg tablet ) daily . 20 mg daily improve median walk distance nearly much 40 mg dose , miss require p value base upon statistical plan . The PHIRST trial first placebo control trial document incremental benefit phosphodiesterase-5 inhibition patient already receive endothelin receptor antagonist . This important implication concept combination therapy PAH . Since tadalafil administer daily , cost therapy less sildenafil , anticipate many patient transition sildenafil tadalafil . The goal prospective retrospective study gather observational data regard switch make , tolerability switch , , extent possible methodology , assess clinical effect switch .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Treatment PAH sildenafil dose 20mg tid great least 30 day Clinical decision convert sildenafil tadalafil therapy Patient consent study participation ( patient already transition sildenafil tadalafil therapy prior study initiation identification patient , patient provide consent use medical record research , retrospective review transition process perform . When possible , patient approach prospective data collection study transition occur less 3 month prior consideration prospective study participation ) Nongroup I PAH Age less 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>